Importantly, BL153 treatment attenuated obesity caused renal inflammation and oxidative stress, which was likely due to the ability of BL153 to increase PGC-1α and HK II expression in kidney. Here, PPARGC1A is linked to obesity due to melanocortin 4 receptor deficiency.